Concentration of MitoQ in Human Skeletal Muscle

Concentration of Mitoquinone Mesylate in Skeletal Muscle After a Single Oral Dose of MitoQ

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04098510

Acronym

MitoQ/muscle

Enrollment

Registered

2019-09-23

Start date

2019-09-08

Completion date

2020-09-30

Last updated

2019-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Mitochondria-targeted antioxidant, Skeletal muscle biopsies

Brief summary

The purpose of this study is to determine mitoquinone mesylate concentration levels in skeletal muscle samples obtained after intake of an acute oral dose of MitoQ.

Interventions

DIETARY_SUPPLEMENTMitoQ

Subjects ingest 8x20 mg MitoQ capsules

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy, * Male * 18-40 years of age

Exclusion criteria

* Previous use of MitoQ or CoQ-10 within 30 days of screening appointment * Ongoing use of MitoQ * Smoking * Ongoing treatment with medications * Disease deemed by the MD to infer a risk to participate in the trial

Design outcomes

Primary

Measure	Time frame	Description
Muscle mitoquinone mesylate concentration	Before oral administration of MitoQ	Concentration of mitoquinone mesylate in skeletal muscle

Secondary

Measure	Time frame	Description
Blood mitoquinone mesylate concentration	Before as well as 0.5, 1, 1.5, 2, 3, 4 and 5 hours after oral administration of MitoQ	Concentration of mitoquinone mesylate in venous blood

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026